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ABSTRACT 
 Low carbohydrate diets have been studied for many years as nutritional therapy 
for treating patients with type 2 diabetes mellitus (T2DM). Type 2 diabetes is an 
inflammatory disease that is defined by high blood glucose and HbA1c, lipid levels, BMI, 
central adiposity, and cholesterol levels, are some among the many indicators that can 
signal risk for diabetes or help to diagnose diabetes. These indicators are used in studies 
to evaluate the effectiveness of the nutritional therapy in producing positive health 
outcomes. Many medications are available for the treatment of T2DM; however, they 
have a host of side effects, and nutritional therapy has been shown to at least help reduce 
the dosage of these medications needed by the patients. There are other forms of 
nutritional therapy besides low carbohydrate diets, and some controversy remains about 
low carbohydrate diets that in the long term, replacing carbohydrates with fats and 
proteins could result in increased cholesterol and lipid levels, creating an increased risk 
for cardiovascular disease. Although some studies have found that low carbohydrate 
diets, especially very low carbohydrate ketogenic diets (VLCK), do result in increased 
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cholesterol, it is generally an increase in HDL, which is considered good cholesterol and 
not harmful. Overall weight loss benefits from reduced central adiposity, BMI, and 
reduced HbA1c levels outweigh the increase in HDL as a side effect. A few different 
variations of low carbohydrate diets are compared in this review, such as very low 
carbohydrate ketogenic diets, moderate carbohydrate calorie restricted diets, and 
moderate carbohydrate low (MCD) Glycemic Index (GI) diets. Due to the ability to 
exchange carbohydrates with high GI for carbohydrates with low GI, the MCD with low 
GI sounds promising for good adherence and positive health outcomes in the long run. 
Although very low carbohydrate ketogenic diets produce many positive health outcomes, 
the nutritional therapy must be very well designed and followed up, and care must be 
taken that fiber and nutrients are maintained in the diet. Adherence is a key part of the 
success of nutritional therapy and a study design plays a major role in that. Providing 
behavioral development classes, nutritional information classes, and intermittent classes 
focused on physical activity and healthy habit formation leads to overall increased 
positive affect which is better for the patient and thus, for the study as well. The easier 
the nutritionist or dietician can make the therapy transition for the participant, the more 
likely they are also to stay and try to stick with it. For example, in the studies where the 
study coordinator provided some small food provisions at the beginning or throughout the 
study seemed to be successful because the patients were less likely to fall to making their 
own choices poorly and being inconsistent. Although there were many diets that resulted 
in many positive health outcomes, ultimately a well-designed, adherence focused, very 
low carbohydrate ketogenic diet seemed to be the most effective at decreasing HbA1c 
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and producing other positive health outcomes as well. In the long term however, a 
VLCKD, may be unsustainable for the patient and the body, given the extreme reduction 
in important carbohydrates.  
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INTRODUCTION 
 
Type 2 Diabetes, also known as Type 2 Diabetes Mellitus, is a disease characterized by 
chronic high plasma glucose. Over time, hyperglycemia and hyperinsulinemia can cause 
patients to develop insulin resistance. Insulin is the hormone involved in regulating 
glucose uptake via GLUT4 transporters in muscle and fat cells. Carbohydrates are 
converted into simple sugars (predominantly glucose) during the process of digestion 
(“Type 2 Diabetes Mellitus”, 2018).  Therefore, it would be reasonable to think that 
reducing carbohydrate intake would reduce plasma glucose levels. Based on that logic, 
many researchers have investigated the effect of low-carbohydrate diets on plasma 
glucose levels in patients with diabetes type 2.  
 
In patients with type 2 diabetes, HbA1c levels (hemoglobin A1c) are used to measure 
their average plasma glucose levels. HbA1c is the term referring to glycosylated 
hemoglobin (Wang et al., 2018). A patient’s glucose levels change throughout the day 
according to meals consumed and activity levels. The HbA1c of a patient allows the 
clinician to get a better picture of the overall average blood glucose levels of a patient 
because it measures the hemoglobin that has been glycosylated in the blood. Red blood 
cells have a lifespan of about 120 days (Shemin D. and Rittenberg D., 1946) and during 
that time they are circulated repeatedly throughout the day, so the hemoglobin that has 
been glycosylated in those red blood cells reflects an average of blood glucose over the 
course of the red blood cells’ lifespan. In experimental studies like the ones discussed in 
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this paper, HbA1c is a good gauge of how well diets have worked to control a patient’s 
blood glucose levels on average (Wang et al., 2018). HbA1c is tested at baseline before 
an experiment and at the end of the experiment, to evaluate the effectiveness of the 
experimental condition, like for example in Figure 1 drawn from Saslow et al. (Saslow et 
al., 2017) 
 
 
 
Figure 1. Moderate Carbohydrate vs. Low Carbohydrate. Mean and Individual 
HbA1c for two experimental groups at baseline and at 6 and 12 months into a 
carbohydrate control experiment.  In the experiment they were placed on a moderate 
carbohydrate diet (left) or a very low carbohydrate diet (right). The graphs demonstrate 
the overall lower mean HbA1c levels in the group on a very low-carbohydrate diet. 
Additionally, the very low-carbohydrate diet group has less individual variance in HbA1c 
levels when compared to the moderate carbohydrate diet group. Figure taken from 
(Saslow et al., 2017) 
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A low carbohydrate diet may refer to one with a daily carbohydrate intake of 
between 30-200 g/day or a daily consumption of carbohydrates that contributes <45% of 
total calories consumed per day (Wang et al., 2018). Throughout this paper, studies with 
low-carbohydrate diets will be reviewed for the overall effectiveness of this diet on 
reducing plasma glucose levels in patients with type 2 diabetes. In these studies, 
whenever a low-calorie diet is included as an independent variable, they may be referring 
to a low carbohydrate diet as a part of a restricted calorie diet overall, or more 
specifically a diet in which total calorie count has not changed, but carbohydrate-based 
calories have been swapped for protein or fat based calories. The variations in low-
carbohydrate diets (i.e. very low carbohydrate diets, moderate carbohydrate diets, and 
low carbohydrate ketogenic diets) will be specified and analyzed in comparison to each 
other in effectiveness.  
 
Effectiveness of a diet will be quantified in this review as the number of positive 
health outcomes and amount of improvement in health outcomes before and after each 
study. The primary health outcome being noted will be controlled blood glucose levels. 
The other health outcome variables that will be used are weight loss, triglyceride levels, 
and cholesterol levels.  
 
Obesity greatly increases the risk of diabetes type 2 in patients (“Type 2 Diabetes 
Mellitus”, 2018). Some studies have looked at specifically obese patients who are pre-
diabetic or have diabetes type 2 to see if low-carbohydrate diets have helped them not 
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only reduce their blood glucose levels as indicated by HbA1c, but also helped them lose 
weight, and reduce their triglyceride and total cholesterol levels. These indicators are 
valuable to track over the course of such experiments because diabetic patients, 
especially those with obesity, have an elevated risk of cardiovascular disease like 
atherosclerosis, which can be fatal (Forsythe et al., 2008).  
 
In addition to indicators of cardiovascular disease, many studies on low-
carbohydrate diet-therapy also analyze the effects of such diets on diabetes controlling 
medication use and need, pre-experiment and post-experiment. In the studies reviewed in 
this paper, many low-carbohydrate diets have proven to reduce the need for blood 
glucose controlling medication in patients with type 2 diabetes (Saslow et al., 2017). In 
other patients with more severe chronic T2DM who have almost non-functioning 
pancreatic beta islet cells and thus, little to no insulin, they are required to take insulin. 
Reducing glucose in their diet, by going on low-carbohydrate diets, these patients have 
also shown that such diets can be effective in helping them reduce their need for insulin 
(Tay et al., 2015). 
 
By analyzing the various factors that predict better health outcomes for patients 
with type 2 diabetes, this review aims to investigate which combinations of independent 
variables in low-carbohydrate diets are the most effective at reducing blood glucose 
levels while providing such additional positive health outcomes. 
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TYPE 2 DIABETES MELLITUS: DIAGNOSIS, TREATMENTS, AND RISKS 
 
Diabetes Link to Cardiovascular Disease 
Diabetes has been linked to cardiovascular disease in various different studies. As 
noted previously, obesity greatly increases diabetics’ risk of cardiovascular disease 
(CVD). To further explore the link between the three – Obesity, CVD, and Diabetes – the 
factors involved in these diseases will be discussed and described to give some 
background on the topics that are included in nearly all studies regarding low-
carbohydrate diet therapies.  
 
Diabetes can be considered an inflammatory disease. There are various sources of 
inflammation that result in elevated levels of proteins such as sialic acid and C-Reactive 
Protein (CRP). This type of inflammation results from cells that are under stress releasing 
cytokines. In people with increased central adiposity and dyslipidemia which are usually 
present in obese adults, the adipocytes go under hypoxic distress and endoplasmic 
reticulum (ER) stress and die off, releasing their contents. The contents of cell debris 
stimulate the release of cytokines, importantly IL-1β and TNF-a. IL-1β is one of the most 
important inflammatory mediators involved in the development of atherosclerosis (Vogel, 
C. et. al., 2005). In a study by Weisberg et. al., it was found that in obesity, adipose tissue 
has significantly increased levels of immune cells. Elevated levels of low-density 
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lipoprotein (LDL) cholesterol in the blood cause inflammation in the walls of our 
medium and large sized arteries resulting in the inflammatory disease state known as 
Atherosclerosis (Galkina, E and Ley, K, 2009). As can be seen in Figure 2, free fatty 
acids and modified LDL stimulate macrophages and adipocytes to produce an 
inflammatory response; such inflammatory responses promote thrombosis which can be 
simply defined as a blood clot that forms which can break free and travel through the 
blood stream to cause an occlusion elsewhere, leading to myocardial infarction or a 
stroke (Libby, P., 2002). This information shows how obesity and inflammation are 
linked to atherosclerosis. Patients with obesity and dyslipidemia are prone to developing 
diabetes, and thus we can see there are a lot of factors in common between the three 
diseases. Since diet plays a major role in these diseases, it is important to understand the 
factors that lie behind them before we discuss how diets can be altered to be curative for 
them.  
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Figure 2. Effect of FFAs and mLDL on Adipocytes. Shows the effect of FFAs and 
mLDL on adipocytes, which can help in understanding the link between obesity and 
inflammation. Taken from (Donath et al., 2013). 
 
 
Metabolic Syndrome is a common diagnosis that brings the aforementioned 
diseases together. It can be diagnosed in a patient with any 3 of the following: abdominal 
obesity, elevated blood pressure, elevated triglycerides, low HDL, and hyperglycemia. 
Gallagher believes that insulin resistance is the link between metabolic syndrome and 
obesity (Gallagher, LeRoith, & Karnieli, 2010).  Future risk of T2DM and CVD can be 
signaled by a diagnosis with metabolic syndrome (Heimburger, D. C. & Ard, J. D., 
2006). That is why in some of the studies discussed later in this paper, symptoms of 
metabolic syndrome and indicators of CVD will be investigated in the subjects of the 
experiments. 
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As for the link between diabetes and CVD, it is still being investigated, but an 
interesting fact is that women with diabetes have an elevated risk for cardiovascular 
disease and coronary atherosclerosis when compared to men with diabetes. C-reactive 
protein (CRP) is a protein that is made by the liver and increased in inflammatory states. 
We know that atherosclerosis is promoted by inflammatory states in the body and since 
CRP is increased due to inflammation, it is suggested that the CRP could be an indicator 
of high risk for an atherosclerotic vascular event. (Colhoun et al., 2002). Although this 
link has been shown, CRP is also made in response to other inflammatory states, and so it 
cannot always be assumed that high levels indicate Atherosclerosis or Cardiovascular 
Disease. However, if the symptoms line up with metabolic syndrome and CRP levels are 
high in a patient with diabetes, especially a woman, one would have good reason to 
investigate for atherosclerosis and CVD.   
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Figure 3. Value of C-Reactive Protein (CRP) as an Indicator. Graphs A – D are 
distributions and mean values of log CRP stratified by tertiles for the following categories: 
SI (Insulin Sensitivity Index) (A), BMI (B), and triglycerides (C). The mean values of each 
category are designated as such: vertical solid lines = first tertile, dashed lines = second 
tertile, and dotted lines = third tertile. In graph A for example, the third tertile represents 
subjects with low insulin resistance aka high SI. In graph D, the solid vertical line depicts 
the mean value of log CRP in hypertensive subjects, whereas the dashed line depicts the 
mean value in non-hypertensive subjects (Festa et al., 2000). Taken from (Festa et al., 
2000). 
 
 
A study was done by Colhoun et. al in 2002 to see if CRP is elevated in type 1 
diabetics and whether it is linked to coronary artery calcification (CAC). In this study 
they found that CRP is generally a valuable marker of subclinical atherosclerosis, but it 
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was not clearly associated with CAC (Colhoun et al., 2002). Figure 3 is a good way to 
visualize the value of CRP as an indicator of BMI, triglycerides, insulin sensitivity (and 
thus insulin resistance), and hypertension – all indicators of metabolic syndrome and 
often tied to diabetes, obesity, and as previously mentioned, cardiovascular disease. 
 
The significant results of the Colhoun et al. study were that CRP was elevated in 
diabetic women compared to nondiabetic women but similar between diabetic and 
nondiabetic men (Colhoun et al., 2000). The amount of insulin needed and taken by 
patients was also positively correlated with CRP in diabetic women. The link between 
diabetes and CRP remains unclear when we see that levels vary between diabetic women 
and men in this study. As for the link between CRP and CAC – even after adjusting for 
other risk factors, CRP was still associated with CAC in diabetic and nondiabetic men in 
the top tertile for CRP (Colhoun et al., 2000). In women, this association was not 
significant. This indicates that in studies done regarding progress in diet for diabetic men, 
testing for changes in level of CRP could be a good indicator for positive outcome of a 
nutritional intervention to keep in mind. An interesting fact from this study is that the 
CRP in diabetic women was elevated but it wasn’t as elevated in diabetic men, and 
Colhoun et. al claim that this could be one of the reasons why diabetic women have such 
a high risk of cardiovascular heart disease when compared to the general population and 
even compared to diabetic men (Colhoun et al., 2000). Why CRP is so much higher in 
diabetic women and why they have higher risk for CVD needs to be investigated for 
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further development in this field. According to this study they adjusted for BMI, 
therefore that cannot be the reason for such a difference.  
 
Previously we discussed how diabetes is an inflammatory disease and adipose 
tissue can become inflamed as well as the endothelial wall of the vasculature, leading to 
increased risk for CVD. CRP is not the only protein that results as an acute phase 
inflammatory indicator; among many others an important one is sialic acid. Sialic acid 
has been shown to be a predictor of cardiovascular disease. In a study performed on 
obese men in India compared to non-obese men, sialic acid was significantly positively 
correlated with insulin resistance, BMI, waist and hip circumference, and negatively 
correlated with the insulin sensitivity index (Rajappa et al., 2013). Obesity has been 
linked to insulin resistance in many studies, but the cause for insulin resistance has not 
been clarified, it has only hypothesized that it may be attributed to the secretion of 
adipokines from adipose tissue (Guilherme et al., 2008). If in fact Insulin resistance is 
resulting from obesity and causing pro-inflammatory cytokines to be released from 
adipocytes in adults with high abdominal adiposity, then we have more reason to be 
inclined toward nutritional plans/diets that have successfully been able to reduce 
abdominal fat, reduce levels of pro-inflammatory cytokines in the blood, and reduce the 
dosage of insulin needed in insulin dependent diabetics. These are factors that will be 
given importance when evaluating diets in the studies reviewed in this thesis.  
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Figure 4. Inflammatory Mechanisms of Beta Cells and Macrophages. Shows the 
effect of FFAs (free fatty acids), mLDL (modified LDL), AGE, and high glucose on 
pancreatic beta cells and macrophages, stimulating the production of cytokines and 
chemokines and other pro-inflammatory agents. Taken from (Donath et al., 2013). 
 
 
 Vascular endothelial cells are damaged in cardiovascular disease and in the 
Donath et al. paper on inflammation and its link to obesity and diabetes, the role of the 
inflammatory mediator IL-1β in initiating and sustaining the disease state is discussed 
(Donath et al., 2013). Figure 4 shows how exactly IL-1β plays a role in inflammatory 
processes in β cells and macrophages. In their study Galea et al. found that the levels of 
IL-1β in a patient’s coronary artery are indicative of the severity of their atherosclerosis 
(Galea et al., 1996). Cholesterol (mLDL) was an agent of distress to adipocytes leading 
them to release cytokines, as can be seen in Figure 2. Cholesterol crystals are also very 
indicative of atherosclerosis when detected in the blood, but they have also been found to 
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induce the release of IL-1β from macrophages in the early stages of atherogenesis 
(Duewell et al., 2010). According to Galkina and Ley, the burden of reactive oxygen 
species (ROS) and advanced glycation end (AGE) products is increased under conditions 
that promote atherosclerosis; the same conditions also reduce nitric oxide production 
from endothelial cells (Galkina, E. & Ley, K., 2009). The endothelial cells are critical to 
proper cardiovascular functioning because the nitric oxide that they produce allows for 
vasodilation. NO can thus be used as an indicator or functional marker of endothelium 
dysfunction when estimated from endothelium-dependent flow mediated dilation (FMD). 
Type 2 diabetes mellitus patients face an increased cardiovascular risk that is 
independently related to impairment in their FMD (Henry et al., 2004).  
 
According to Barbosa-Yanez, endothelial dysfunction has been associated with 
T2DM, Nonalcoholic fatty liver disease (NAFLD), and excessive fat mass (Barbosa-
Yañez et al., 2018). In a study by Colak et al. assessing endothelial function in patients 
with NAFLD, they found that carotid artery intima-media thickness (C-IMT) (detected 
using vascular ultrasound) was higher in patients with NAFLD. NAFLD has been linked 
to CVD and also T2DM, as the patients tend to be obese or have high serum lipid levels, 
which as discussed is also a pro-inflammatory factor in these diseases (Adams et al., 
2010). In a study done to see if NAFLD increased risk of death in patients with T2DM, it 
was found that NAFLD was more common in younger and female patients who were 
obese. They found that overall mortality was significantly associated with a diagnosis of 
NAFLD, presence of ischemic heart disease, and duration of diabetes (Adams et al., 
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2010). This ties together the previous articles indicating a higher CVD risk in women 
with diabetes to NAFLD as another risk factor. From these studies we can note that C-
IMT and FMD are good indicators of NAFLD and endothelial dysfunction which may 
also be used as indicators of positive or negative health outcomes in a diet-based study of 
diabetics.  
 
In a study done by The British Diabetic Association to measure cause specific 
mortality in patients with insulin-treated diabetes mellitus, it was found that the largest 
proportion of deaths in people aged 30 and up was caused by CVD (Laing et al., 1999).  
The fact that NAFLD, T2DM, Insulin Resistance, Obesity, Metabolic Syndrome, 
Inflammation, are all tied to CVD indicates that it will be important to watch risk factors 
for CVD and its associated diseases when evaluating the effectiveness of diets since the 
most major cause of mortality in Diabetics is CVD. So far these risk factors have 
included: C-Reactive Protein levels, sialic acid levels, FMD to gauge endothelial 
function, C-IMT, serum lipid levels, LDL cholesterol levels, FFA levels, IL-1β levels, 
central adiposity, gender, all symptoms of metabolic syndrome, NAFLD diagnosis, and 
decreased insulin sensitivity.  
 
Diabetes Medication and Insulin for T2DM 
There are various different pharmaceutical therapies for type 2 diabetes mellitus 
available and being used around the world. As mentioned previously, HbA1c levels in 
patients’ blood are used to gauge the extent of disease and the need for drugs in patients, 
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as well as the effectiveness of drugs or other therapies. In the U.S. target HbA1c levels 
are considered to be 7% or less, however less than 5.7% is what’s considered normal. 
Patients with HbA1c levels between 5.7-6.4% are considered prediabetic and often 
recommended diet therapy, exercise, and/or given low dose metformin on the upper end 
of the spectrum. Metformin is a drug that lowers glucose production in the liver and 
increases insulin sensitivity, it is generally the preferred starter medication for newly 
diagnosed diabetics because it has few side effects, such as diarrhea and nausea, which 
tend to subside with extended use. Other drugs have different mechanisms but ultimately 
aim to increase insulin secretion in individuals who have developed decreased insulin 
sensitivity and/or have reduced beta islet insulin production in the pancreas from 
damaged islet cells.   
 
Sulfonylureas and Meglitinides make the pancreas secrete insulin, but 
Meglitinides are faster acting; both of these drugs have the potential to cause low blood 
sugar and weight gain, which is why they have been discontinued in patients prior to 
some of the diet therapy studies as a safety measure to prevent hypoglycemia that could 
result from reduced carbohydrate consumption paired with increased insulin secretion. 
Additionally, it should be noted that since these drugs tend to cause weight gain, if a diet 
therapy study is done in which these drugs are discontinued in the patients who normally 
use them, weight loss may occur as an effect of discontinuing the drug use as opposed to 
actual diet-related weight loss (Mayo Clinic, 2017). Thiazolidinediones are another class 
of drugs used to treat T2DM and they work by increasing insulin sensitivity; however, 
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thiazolidinediones are risky, as their side effects include anemia and increased risk of 
heart failure, therefore they are not usually the first choice for medications (Mayo Clinic, 
2017). Other diabetic medications include DPP-4 inhibitors and GLP-1 agonists, both of 
which help reduce blood glucose levels but in most cases are not effective enough to be 
worth their side effect risks of pancreatitis and heart attack or stroke, respectively. Insulin 
can be and is used in some cases as well, depending on the severity of the patient’s 
disease.  
 
SGLT2 inhibitors prevent reabsorption of glucose from blood filtrate at the level 
of the kidneys. These drugs can help reduce the risk in people with an increased risk of 
heart attack and stroke; however, the other side effects of the drug include increased risk 
of low blood pressure and diabetic ketoacidosis.  (Mayo Clinic, 2017).  
 
In T2DM nutritional therapy, reduction in the need for use of drugs is seen as a 
measure of improved health and success of a study. This improvement in health can be 
contextualized by the aforementioned side effects of the drugs often prescribed for 
T2DM. A change in required dosage of a drug also means that the patient must have a 
reduced percentage of HbA1c as a result of the nutritional therapy such that they could 
reduce their dosage of drugs.  
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Nutrition Therapy for Type 2 Diabetes Mellitus 
Nutrition Therapy for T2DM includes special diets designed to help patients lose 
weight and recover from hyperglycemia and reduce their need for medication. Since 
diabetes can be evaluated based on blood glucose levels in patients, or amount of 
glycated hemoglobin in the blood, cutting down a major source of glucose in the diet – 
carbohydrates – has proven successful at improving the condition of T2DM patients. 
Very many studies have been successful at showing that the reduction in carbohydrates 
consumed leads to reduced levels of HbA1c, as can be seen in the chart below. Figure 5 
compares the starting and ending HbA1c levels in a few different experiments that shared 
low carbohydrate nutritional therapy as an experimental condition.  
Figure 5. Change in HbA1c Percentages. This image shows the comparative HbA1c 
percentages from baseline to endpoint in different nutritional therapy studies in their LCD 
condition. Although they vary in exact experimental conditions, overall the trend is the 
same.  
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Feinman et al. defines the various different types of low carbohydrate diets based 
on gram amounts of carbohydrates and they have been listed in Table 1 below.  
 
Table 1. Carbohydrate Restrictive Diets. A table of carbohydrate restrictive diets 
defined based on definitions provided by Feinman, D. Richard et al. (Feinman et al., 
2015). 
 
Very Low Carbohydrate Ketogenic Diet 20-50g/d or <10% of total energy 
consumed 
Low Carbohydrate Diet <130g/d or <26% total energy consumed 
Moderate Carbohydrate Diet <200g/d or 26-45% of total energy 
consumed 
 
 
Adherence in Nutritional Therapy  
Often times these low carbohydrate diets are paired with recommendations for 
increased physical activity and mindful eating. In a study by Saslow et al., they 
conducted a study to compare the effectiveness of a Low Carbohydrate Ketogenic Diet 
(LCK) vs. a Moderate Carbohydrate Calorie Restricted Diet (MCCR). In that study they 
implemented a class format to maintain adherence to the experimental conditions and to 
help the patients holistically improve their lifestyle to benefit their disease state. They had 
participants attend 19 classes over 12 months with class leaders coaching them on 
mindful eating, the importance of sleep and exercise, all the while trying to increase 
positive affect (Saslow et al., 2017). As a result of holistically approaching patient health 
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and working to maintain good patient adherence, Saslow et al. retained 85.3% of their 
participants. Overall the LCK diet group: improved their HbA1c levels more than the 
MCCR group, lost more weight and lowered their BMI more compared to the MCCR 
group, and lowered use of medications for diabetes more than those in the MCCR group. 
The main problem with a nutritional therapy study that works to maintain adherence like 
this one is that in the end they were unsure whether improved behaviors – such as better 
sleep schedules and routine exercise paired with positive affect – were the cause for the 
extent to which indicators of better health improved in either experimental condition.  
 
Some studies take a more technical approach to nutritional therapy, for example 
Sato et al. did a year-long randomized control trial comparing calorie restricted diets to 
low carbohydrate diets in which the subjects had follow-up appointments with dieticians 
after being assigned an experimental condition (Sato et al., 2017). As opposed to 
adherence classes working to holistically improve the mindset of the participant such that 
they may adhere better to the test condition, this type of study focuses more closely on 
adherence to the exact nutritional recommendations, reinforced by nutritional education 
sessions. Studies like this and the one conducted by Saslow et al. however, must be 
evaluated with the knowledge that they cannot guarantee similar success if replicated in 
clinic without the level of follow-up and education provided to the participants as in these 
studies.  
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Adherence, not only depends on the behavioral therapy and professional support 
received throughout the study, it also depends on the way the information is presented 
and how manageable the diet is. The subjects enrolled in these studies are meant to reflect 
the average T2DM patient seeking nutritional therapy to help improve their disease state. 
It should be expected that patients will have a certain lifestyle and varying eating habits 
that will conflict with the diets set as therapeutic conditions. However, it is important that 
these challenges be considered in the studies to best address them when presented in real 
life therapy.  
 
Wang et al. conducted a study comparing the effectiveness of LCD vs. LFD as 
therapy for T2DM. This is a good case study to look at when thinking about how to 
address the challenges of making major changes to patient’s diets and still having good 
adherence, because they managed to have high retention (about 86%) and only lost 1 
participant in follow up for the LCD group. The Wang et al. study can serve as an 
example for future studies because they maintained adherence to a low carbohydrate diet 
in China, where rice is a staple food. One can argue that this study’s success was made 
possible by utilizing the 6-point formula detailed in Figure 6. Other studies have 
provided booklets on what to eat based on their diet, but a simple diagram is easier to 
follow and easier on the eyes than a booklet full of information. Developing this type of 
formula diagram could be possible for multiple different regions based on their staple 
foods, dietary restrictions, availability, and accessibility.  
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Accessibility is another factor of adherence to consider when looking to low carbohydrate 
nutritional therapy as a means of producing positive health outcomes in T2DM patient 
populations. Thus far, low carbohydrate diets, especially very low carbohydrate 
ketogenic diets have proven to show long term benefits in improving HbA1c percentages 
and reducing blood glucose levels. Additionally, low carbohydrate ketogenic diets have 
been shown to reduce significant amounts of weight, and central adiposity, and 
intrahepatic lipid content (IHL) in patients, which are all positive health outcomes we 
were looking at to evaluate the effectiveness of these diets.  The accessibility aspect of 
these diets comes in with the experimental/diet design. If more studies/clinics would 
provide parts of the meal plan for the patients as they did in Wang et al. with pre-
packaged nuts, or in Wolever et al. with pre-weighed portions of starchy foods, cheese, 
and tinned sauces for their diets it would be better for patient adherence to diets and also 
patient retention in studies. If patients are either financially unable or if they live in a 
food desert, it may be impractical to place them on a certain type of low-calorie diet 
when they cannot access the necessary foods.  
 
Another study used a meal replacement drink and offered each subject the choice 
to consume an extra 200mg raw or steamed veggies every day (Barbosa-Yañez et al., 
2018). It is believable that perhaps these people may have been more successful despite 
their extremely restricted low calorie and low carbohydrate diet because they were given 
something that staved off hunger and cravings.  That is another reason why LCK diets are 
a good idea but rely heavily on the execution and design of the therapy.  
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Figure 6. 6-Point Formula. “Notes: 1 jin = 10 liang = 500 g, Chinese conventional units 
of weight. Staple food/meal refers to foods rich in carbohydrates, mainly three kinds of 
steamed bread, noodles, and rice in China” (Wang et al., 2019). Taken from (Wang et al., 
2019). 
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LCD vs. LFD: increased CVD risk 
 In another review about ‘dietary carbohydrate restriction in diabetes 
management’, Feinman et al. notes that before the use of insulin to treat T2DM (and 
slightly afterwards) carbohydrate restriction diets were successful, and commonplace in 
the treatment of T2DM. Later on, this type of dietary intervention fell out of practice by 
some, possibly due to suspicion that the replacement of dietary carbohydrates with fats in 
a low carbohydrate diet would lead to adverse effects such as increased CVD risk.  
 
In order to evaluate the risk of an LCD vs. LFD, we can take a look at a 2017 
article by Sato et al. comparing LCD and LFD. In their study they found that the LFD 
group had significantly greater enhancement of FMD when compared to the LCD group 
(Sato et al., 2017). Similar results were found by Barbosa-Yañez et al. in their study 
comparing VLCKD and LF diets. Barbosa-Yañez et al. also found that there was a 
significantly greater decrease in total cholesterol and LDL in the LFD compared to the 
VLCKD (Barbosa-Yañez et al., 2018). Sato et al. found that both experimental groups 
had reduced body weight, body fat content, and intrahepatic lipid content (IHL) by the 
end of the study (Sato et al., 2017). As discussed before, central adiposity and obesity 
have been associated with endothelial dysfunction and inflammatory disease. Cholesterol, 
specifically LDL levels are also important in determining CVD risk, based on endothelial 
dysfunction caused by inflammation, as shown in Figure 4. From that information it can 
be noted that perhaps a low-fat diet is better in reducing risk for CVD, by reducing total 
cholesterol, LDL, and improving FMD. However, it should be noted that there is not 
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significant evidence in these studies that an LCD increases risk for CVD. In fact, since 
both experimental conditions in more than one study resulted in significant weight loss, 
decreased body fat content, and decreased IHL, we can conclude that both an LCD and 
an LFD help reduce risk of CVD.  
 
In a comparison study of an LCD to an LFD by Davis et al., differences in risk for 
CVD can be observed between the two diet conditions in the short term, but long-term 
diet adherence has resulted in similar changes in either diet group. For example, overall 
weight loss by 12 months was the same between the groups. The only notable change is 
that the LCD diet showed an increase in HDL in participants as compared to low fat diet 
participants. However, HDL is the less disruptive type of cholesterol to the endothelial 
wall of our vasculature, hence why it is often called “good cholesterol” – as opposed to 
LDL which is called “bad cholesterol” due to its vascular endothelial inflammation 
inducing tendency. Therefore, we can see once again that there is not much difference in 
risk of CVD between the two LCD and LFD groups (Davis et al., 2012)  
 
Which LCD works best: LCD vs. VLCKD vs. MCCR vs. low GI MCD 
Low carbohydrate diets have been shown to reduce weight, BMI, HbA1c levels, 
and dose of diabetes medication needed. However, there are 3 variations of LCD that are 
used in various different studies and the goal of this review has been to reason out which 
is best. However, as discussed thus far, there are so many variables that play a major role 
in the extent of success of nutritional therapy that no diet is perfect without a good 
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supporting experimental design. Putting together the design aspects discussed thus far, 
we can deduce which combination of study design and low carbohydrate diet has been 
the most fruitful, so that future studies can carry out a longer-term study evaluating it 
further.  
 
Generally, a high carbohydrate diet would be considered harmful for a diabetic 
patient since it would increase blood glucose and insulin levels leading to resistance. One 
thing that has been widely dismissed in this nutritional field is maintaining a low 
glycemic index for one’s carbohydrate meals rather than drastically reducing 
carbohydrate consumption altogether. This method is better for accessibility and 
adherence, in that one can still consume carbohydrates, but simply exchange them for 
carbohydrates with low GI. According to Wolever et al. the negative consequences for 
T2DM individuals consuming high levels of carbohydrates are reduced when the 
carbohydrates are those with a low GI (Wolever et al., 2019). Previously it had been 
considered that GI monitoring had no place in nutritional therapy because everyone has 
slightly different glycemic responses to foods and the difference in glycemic response 
between a low GI and a high GI carbohydrate were not significantly different enough to 
have clinical significance. This study proved that wrong, in that it was clear that on a low 
GI diet, even moderate carbohydrates could be consumed while still resulting in positive 
health outcomes such as decreased overall blood glucose and serum cholesterol (both 
observed in this study).  
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Very low carbohydrate ketogenic diets seem to be the most popularly studied and 
generally very successful at reducing weight, BMI, and HbA1c. The concerns about 
increased risk for CVD can be dispelled as we discussed earlier, because increased 
protein or fat intake may alter HDL and lipids but overall reduction in weight and BMI 
leads to decreased central adiposity which is an important risk factor for CVD, especially 
in women with T2DM who have an increased risk for CVD. Barbosa Yañez did a study 
comparing a VLCKD to an LFD, and the study design implemented a calorie restricted 
model with flavored meal replacement protein powder called MODIFAST and an 
allowance of 200 mg of raw or steamed vegetables (Barbosa Yañez et al., 2018). 
According to a recent article published in JAMA Internal Medicine, the consequences of 
restricting one’s carbohydrate intake in a low carbohydrate ketogenic diet is that one’s 
high-fiber, unrefined carbohydrate consumption also becomes restricted, so it is good that 
this study incorporated the extra vegetable allowance for the fiber (Joshi, Ostfeld, 
McMacken, 2019). The results of this VLCK indicated that HbA1c levels significantly 
declined in the VLCK group, which is a positive health outcome, but the study was only 
3 weeks long so it is not clear whether this outcome will last.  
 
Another study that evaluated a VLCK diet was conducted by Saslow et al. but it 
was conducted for 12 months with a 3-month, 6-month, and 12-month follow up. This 
study specifically compared the low carb ketogenic diet to a moderate carb calorie 
restricted diet, which is of interest because an MCCR is seems easier to adhere to than a 
VLCK diet with all of its restrictions. At the 3 months follow up the VLCK group had 
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improved glycemic control and lost more weight than the MCCR group. After 6 months 
twice as many VLCK participants had improved HbA1c levels as compared to the 
MCCR participants. Finally, after 12 months the LCK group reduced their HbA1c levels 
more, lost more weight, lowered their BMI more, and lowered their use of their diabetes 
medications more than the MCCR group. These are all very positive health outcomes 
pointing to VLCK as a more successful nutritional therapy option than MCCR; however, 
the study only included 34 participants so it is not wide enough to make a generalization.  
 
Sato et al. evaluated just a low carbohydrate diet vs. a calorie restricted diet, and 
this specific study defined low carbohydrate as 130g, so it is not low enough to be 
ketogenic, but still low enough to produce results (Sato et. al, 2017). It was found in their 
previously conducted randomized control trial that HbA1c and BMI decreased more 
significantly in the LCD than the CRD group. However, in the follow up second study 
they observed the patients in the both groups at 18 months from the start of the initial 
study and found that there was significant improvement in LDL cholesterol in both and 
no significant difference between the positive outcomes noted for either group. Thus, it 
cannot be concluded that LCD is better than a CRD, even though the MCCR diet from 
the Saslow et al. study turned out to be less beneficial than the VLCK diet. Since the Sato 
et al. study was longer term, its data may be more credible (Sato et al., 2017).  
 
From these studies and more, we can determine that perhaps the LCK with low GI 
carbs is the most successful in producing positive health outcomes in T2DM patients and 
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being the easiest to implement, at least in the short term, and thus may be worth 
incorporating into a broader holistic therapy for treating the disease.  
 
Short term vs. long term effectiveness 
Given that the goal of this thesis is to compare different low carbohydrate diets in 
studies to determine which is most effective, we must take a look at both short term and 
long-term effectiveness in multiple different studies to compare them. Although both the 
Saslow et al. and Sato et al. studies showed improvement in HbA1c from baseline to end 
point, Sato et al. found that 18 months after baseline, there were no differences between 
the two conditions – LCD and CRD – in factors observed as indicators of positive health 
outcome (i.e. body weight, BMI, HbA1c levels). Even though there was no significant 
difference between the two experimental conditions in the long term, there was a 
significant improvement in positive health indicators overall in both LCD and CRD 
groups from baseline to the 18-month mark, so both diets are effective to a degree (Sato 
et al., 2017) (Saslow et al., 2017).  
 
Low GI vs. High GI diets are notable because the future of low carb diets may 
include measuring GI so that the subjects can maximize satisfaction of carb consumption 
without hurting their diet/health prospects at the same time (Wolever et al., 2019). In the 
short term, a low GI calorie restricted low carb diet was studied by Wolever et al. and it 
was found that there wasn’t a lot of weight loss over the 6-week periods in which the 
study was conducted, but there was significant reduction in TG levels and fasting blood 
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glucose levels fell along with cholesterol levels and serum fructosamine. These health 
outcomes indicate reduced blood glucose and overall improvement in health, so it was 
successful in the short term.  
 
  Another more complex variation on nutritional therapy focused on carbohydrate 
monitoring was carried out in a study by Due et al. comparing a moderate fat (40%) 20% 
MUFA and low GI diet to low fat (25%) medium GI diet. The moderate fat 20% MUFA 
and low GI diet resulted in higher attrition rate from the study, however it also resulted in 
the best improvement in LDL/HDL ratio compared to the control diet of 35% fat and 
high GI. Although the health outcomes were more positive for the moderate fat 20% 
MUFA and low GI diet, the low-fat medium GI diet was easier to adhere to.  This study 
was an 18-month trial and at the end they found that the LF diet was generally more 
satisfactory as well as easier to follow, although it didn’t result in the biggest reduction in 
LDL/HDL ratio. In the long term they both produced similar weight regain and 
significantly reduced LDL/HDL ratio so both diets can be considered successful and 
useful for future nutritional therapy.  
 
 A lot of the studies experienced weight regain and decreased adherence to diet 
past the first 3 months of a study. That shows that any study in the long term, to be 
effective study designs need to be very holistic and involved in the patient’s life as 
previously discussed, so that there is motivation to keep going despite the challenges that 
therapy might present.  
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CONCLUSIONS 
 
Type 2 diabetes mellitus is linked to cardiovascular disease because of 
inflammatory mediators stimulated by high blood lipid levels (FFAs) and high LDL that 
are common in obese and overweight individuals. For unknown reasons, women with 
T2DM are more at risk for CVD than men. Obese women or those with high serum LDL 
can benefit from low carbohydrate diets since they produce weight loss that leads to 
reduction in dyslipidemia in their circulation and lowered levels of blood glucose and 
HbA1c. Obese men can also benefit from such low carbohydrate diets and may benefit 
from a moderate carbohydrate low GI diet since that would allow them to lose weight but 
not have to cut out as many carbohydrates and still have filling meals.  
 
T2DM men and women regardless of their physicality, can benefit from any 
variation of LCD that has been discussed because they all manage to reduce HbA1c and 
sustain that result regardless of any other parameter mentioned thus far. Diabetic 
medications can present a lot of side effects and using a nutritional therapy can help 
reduce the dosage of the drug the patient needs. For some of the more harmful drugs that 
can lead to increased risk of things like pancreatitis or stroke, it is an obvious choice to 
receive nutritional therapy to reduce the disease symptoms and severity.   
 
 More important than which diet is chosen, was which experimental design was 
used and what benefits did it have. Some that are notable and should be further 
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investigated in future studies include: provisioning partial or entire diet foods, creating a 
concise and straight forward formula/diagram to detail what a patient’s daily meal 
planning should consist of in order to best adhere to the study, maintain 
traditional/cultural norms of eating based on region when designing dietary 
recommendations, and holistic involvement in patient’s lives to improve positive affect 
and overall behavioral tendencies. With these aspects in a study, retention and adherence 
should be longer term, resulting in more long term sustained results. To guide a patient to 
change their lifestyle through dietary choices, should be the goal of nutritional therapy. 
Patients will not be fully cured of their disease or have a better lifestyle after a month-
long diet change. There is a need for a longer-term trial (>18 months) with all of the 
aforementioned features and multiple follow-ups for years in a patient’s life after the 
nutritional therapy. Such a trial would be hard to manage and very complex when trying 
to get involved in patient’s lives on a broader level. One would presume that there would 
need to be a lot of work put into analyzing all of the independent variables in conjunction 
as one experimental condition. There is a lot of potential for confounding variable and 
factors in a study that gets so involved in a patient’s holistic lifestyle. In order to 
accomplish a study as complex as that the experimental design would have to be very 
meticulous and draw from all the shortcomings in the designs of other nutritional therapy 
studies.   
 
 Thus far the biggest short comings apparent in these studies have been a poor 
follow-up system and lack of clear and concise nutritional education. In addition, one of 
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the strongest points to studies that achieved many positive health outcomes was the 
provisioning of some food items that helped to maintain a consistency between different 
patients on the same diet.  In future studies it would be important to have a large sample 
with a nearly equal number of men and women in the experimental conditions so that 
comparative analysis could be made between how the therapy affects the women vs. the 
men. The fact that women have that increased risk of CVD presents the need to carefully 
pay attention to the variables in the diet that cause a reduction in CVD risk and whether 
that risk is increased or decreased at a different rate or to a different extent between men 
and women.  It would be interesting to see in a larger study whether men and women are 
differently impacted by the nutritional therapy, for example perhaps one group might 
have a greater reduction in HbA1c vs the other under the same experimental conditions.  
 
In the future, one would like to see studies where the diets are more complex such 
that they involve the positive features of many different diets incorporated into one. For 
example, a diet could include moderate carbohydrates with low GI and moderate fat with 
a controlled amount of monounsaturated fatty acids, while still maintaining a restricted 
number of calories. Provisioning of MODIFAST like protein shakes used in the study by 
Barbosa-Yañez et al. or pre-packaged nuts like in Wang et al. could help to keep the 
patients full and nourished, yet still reduce weight significantly. The difficulty with a 
complex diet like that would be preventing hypoglycemia, so they would have to 
carefully monitor blood sugar levels and likely discontinue medications that alter insulin 
secretion/sensitivity in the duration of the study. Also, adhering to the tastes and regional 
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differences in dietary habits, as well as accessibility and availability of certain foods may 
complicate this study design further but I believe a more integrated holistic approach to 
nutritional therapy will be the more effective path to take when looking to have longer 
term positive health outcomes. 
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